We are a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health and reduce cardiovascular risk. Our commercialized product, VASCEPA (icosapent ethyl), was first approved by the FDA in July 2012 to reduce triglyceride levels in adult patients.
Partnerships Seven commercial partners: Edding (China Territory — $25M Recordati-style; tiered double-digit royalties, up to $120M sales milestones), HLS Therapeutics (Canada — up to $47.5M sales milestones + tiered royalties), Biologix (MENA), CSL (Australia/New Zealand), Recordati (59 European countries, Jun 2025 — $25M upfront, up to $150M sales milestones + royalties), Neopharm (Israel), Lotus (ASEAN); Mochida (Jun 2018 collaboration to research/develop new EPA-based products and indications — still early stages, no named asset)
Indications
Severe hypertriglyceridemia (MARINE indication)(Approved)
CV risk reduction in statin-treated high-risk patients (REDUCE-IT indication)(Approved)
Status note Single commercial product; no clinical-stage pipeline in the filing. U.S. FDA approved Jul 2012 (MARINE) and Dec 2019 (REDUCE-IT); EC approved Mar 2021 as VAZKEPA. Several MARINE-indication patents invalidated Mar 2020 (Nevada court; appeals exhausted); generics from Dr. Reddy's and Hikma approved for MARINE indication in U.S.
Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.